The synthetic biology company Gen9 has raised $25 million in equity financing for its work on a next-gen gene synthesis platform technology. Cited by The Scientist back in 2012 as the number 1 innovation of the year, Gen9 has been building its BioFab platform to spawn synthetic genes for customers at a relatively low price, cutting the cost of DNA synthesis for the industry. And their scientific advisory board includes the likes of George Church from Harvard and MIT's Joseph Jacobson, the co-founder and executive chairman. The Cambridge, MA-based biotech landed a $21 million investment from Agilent last year. Filing